In Vitro and In Vivo Evaluation of Small Cationic Abiotic Lipopeptides as Novel Antifungal Agents

Chemical Biology & Drug Design
Sandeep LohanGopal Singh Bisht

Abstract

We investigated the antifungal potential of short lipopeptides against clinical fungal isolates with an objective to evaluate their clinical feasibility. All tested lipopeptides exhibit good antifungal activity with negligible difference between the MICs against susceptible and drug-resistant clinical fungal isolates. The MTT assay results revealed the lower cytotoxicity of lipopeptides toward mammalian cells (NRK-52E). In particular, LP24 displayed highest potency against most of the tested fungal isolates with MICs in the range of 1.5-4.5 μg/mL. Calcein dye leakage experiments with model membrane suggested the membrane-active mode of action for LP24. Extending our work from model membranes to intact Aspergillus fumigatus in scanning electron micrographs, we could visualize surface perturbation caused by LP24. LP24 (5 mg/kg) significantly reduces the A. fumigatus burden among the various organs of infected animals, and 70% of the infected mice survived when observed for 28 days. This study underscores the potential of small cationic abiotic lipopeptides to develop into the next-generation antimicrobial therapy.

References

May 1, 1995·Biophysical Journal·R Maget-Dana, M Ptak
Jan 1, 1994·Annual Review of Microbiology·M Debono, R S Gordee
Jan 25, 2002·Nature·Michael Zasloff
Jan 8, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Juergen Loeffler, David A Stevens
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·Valérie Letscher-Bru, Raoul Herbrecht
Oct 11, 2003·Lancet·David W Denning
May 23, 2006·Current Medicinal Chemistry·Sandeep SundriyalRahul Jain
Jul 15, 2006·Molecular Plant-microbe Interactions : MPMI·Jos M RaaijmakersMaarten J D de Kock
Oct 14, 2006·Proceedings of the National Academy of Sciences of the United States of America·Arik MakovitzkiYechiel Shai
May 26, 2007·International Journal of Antimicrobial Agents·George Petrikkos, Anna Skiada
Apr 9, 2010·Chemical Biology & Drug Design·Garry LavertyBrendan F Gilmore
May 17, 2011·Cellular and Molecular Life Sciences : CMLS·Amy T Y YeungRobert E W Hancock
Jul 4, 2013·Chemical Biology & Drug Design·Sandeep LohanGopal S Bisht
Aug 7, 2013·Annals of Medical and Health Sciences Research·Sj Bajwa, A Kulshrestha
Mar 19, 2014·Transplant Infectious Disease : an Official Journal of the Transplantation Society·J S SchieffelinG A Pankey
Jun 1, 2014·Bioorganic & Medicinal Chemistry Letters·Amit MahindraRahul Jain
Jun 6, 2014·ACS Medicinal Chemistry Letters·Amit MahindraRahul Jain

❮ Previous
Next ❯

Citations

Sep 27, 2019·Mini Reviews in Medicinal Chemistry·Deepika Sharma, Gopal Singh Bisht

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.